Corbus Pharmaceuticals' (CRBP) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Corbus Pharmaceuticals' stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, indicating ongoing concerns about its performance.
• The company has experienced a significant 342% year-to-date surge in stock price, amidst mixed ratings from analysts, with price targets varying widely.
• Corbus Pharmaceuticals recently reported an EPS of ($1.44) for the quarter, exceeding analyst estimates, while institutional investors hold approximately 64.64% of the company's stock.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

Other analysts also recently issued research reports about the company. Piper Sandler reaffirmed an "overweight" rating and issued a $51.00 target price on shares of Corbus Pharmaceuticals in a research report on Monday. Wedbush boosted their price target on Corbus Pharmaceuticals from $31.00 to $38.00 and gave the stock an "outperform" rating in a research report on Monday. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday. Benchmark reissued a "reduce" rating on shares of Corbus Pharmaceuticals in a research note on Monday. Finally, B. Riley upgraded shares of Corbus Pharmaceuticals to a "strong-buy" rating and set a $28.00 target price on the stock in a report on Wednesday, July 30th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $45.86.

Corbus Pharmaceuticals Price Performance

Shares of CRBP traded down $0.50 during mid-day trading on Friday, hitting $16.88. 188,648 shares of the company's stock were exchanged, compared to its average volume of 377,369. Corbus Pharmaceuticals has a 52 week low of $4.64 and a 52 week high of $20.77. The company has a market cap of $206.95 million, a PE ratio of -3.55 and a beta of 2.84. The company has a 50-day simple moving average of $12.49 and a 200 day simple moving average of $9.45.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) EPS for the quarter, topping analysts' consensus estimates of ($1.55) by $0.11. On average, analysts anticipate that Corbus Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Corton Capital Inc. acquired a new stake in Corbus Pharmaceuticals during the 2nd quarter valued at $86,000. Marshall Wace LLP acquired a new position in shares of Corbus Pharmaceuticals in the second quarter valued at $137,000. Baker Avenue Asset Management LP bought a new position in shares of Corbus Pharmaceuticals in the second quarter valued at about $138,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Corbus Pharmaceuticals during the 2nd quarter worth about $141,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals during the 1st quarter worth about $186,000. Institutional investors own 64.64% of the company's stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.